Drug Trial Radar · NCT05757570
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 3, 2023
Primary completion
Aug 12, 2026
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- Alpine Immune Sciences Inc, A Subsidiary of VertexIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Conditions
- Idiopathic Thrombocytopenic Purpura
- Immune Thrombocytopenia
- Warm Autoimmune Hemolytic Anemia
- Cold Agglutinin Disease
Interventions
PovetaciceptDrug
Administered by subcutaneous injection every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)Time frame: Study Day 1 through 30 days after last dose of study drug
Locations
44 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site (230)
Los Angeles, California
Investigational Site (401)
Washington D.C., District of Columbia
Investigational Site (419)
Cooper City, Florida
Investigational Site (425)
Miami, Florida
Investigational Site (219)
Iowa City, Iowa
Investigational Site (435)
Columbia, Maryland
Investigational site (405)
Lake Success, New York
Investigational Site (423)
New Hyde Park, New York
Investigational Site (421)
New York, New York
Investigational Site (404)
New York, New York
Investigational Site (420)
Shirley, New York
Investigational Site (422)
The Bronx, New York
Investigational Site (414)
Charlotte, North Carolina
Investigational Site (402)
Greenville, North Carolina
Investigational Site (411)
Seattle, Washington
Investigational Site (410)
Box Hill, Australia
Investigational Site (519)
Concord, Australia
Investigational Site (517)
Douglas, Australia
Investigational Site (413)
Liverpool, Australia
Investigational Site (407)
West Perth, Australia
Investigational Site (409)
Westmead, Australia
Investigational Site (434)
Vienna, Austria
Investigational Site (406)
Greenfield Park, Canada
Investigational Site (403)
Hamilton, Canada
Investigational Site (444)
Toronto, Canada
Investigational Site (438)
Essen, Germany
Investigational Site (432)
Meldola, Italy
Investigational Site (428)
Milan, Italy
Investigational Site (431)
Novara, Italy
Investigational Site (443)
Trieste, Italy
Investigational Site (433)
Grålum, Norway
Investigational Site (437)
Trondheim, Norway
Investigational Site (436)
Barcelona, Spain
Investigational Site (429)
Burgos, Spain
Investigational Site (430)
Madrid, Spain
Investigational Site (426)
Murcia, Spain
Investigational Site (427)
Seville, Spain
Investigational Site (415)
Ankara, Turkey (Türkiye)
Investigational Site (416)
Ankara, Turkey (Türkiye)
Investigational Site (418)
Istanbul, Turkey (Türkiye)
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.